Solive Tablet 5 mg (Solifenacin Succinate)

Adult dose

The usual recommended dose for adults (including elderly patients) is 5mg once daily. If necessary, the dose may be increased up to 10mg once daily. This drug may be taken irrespective of meals and should be swallowed whole with water. Dosage adjustment is required for the following patients. 1. Patients with renal impairment: No dose adjustment is required for patients with mild or moderate renal impairment (creatinine clearance>30ml/min). In patients with severe renal impairment (creatinine clearance≤30ml/min), administer with caution and do not exceed 5mg once daily. 2. Patients with hepatic impairment: No dose adjustment is required for patients with mild hepatic impairment. In patients with moderate hepatic impairment (Child-Pugh Class B), administer with caution and do not exceed 5mg once daily. 3. Patients receiving a strong cytochrome P450 3A4 (CYP3A4) inhibitor: For patients receiving ketoconazole or another strong CYP3A4 inhibitor (e.g., ritonavir, nelfinavir, itraconazole), limit the maximum daily dose to 5mg.

This medication should not be used in patients with urinary retention symptoms, severe gastrointestinal problems, myasthenia gravis patients, and patients with narrow-angle glaucoma. Additionally, it should not be administered to patients with known hypersensitivity to this drug or its components, patients undergoing hemodialysis, patients with severe liver dysfunction, patients with severe renal dysfunction or moderate liver dysfunction who are taking potent CYP3A4 inhibitors, and patients with certain genetic issues. This drug should be used with caution in patients at risk of urinary retention or gastrointestinal obstructive diseases, reduced gastrointestinal motility, severe renal dysfunction, or moderate liver dysfunction. Also, it should be carefully administered in patients taking strong CYP3A4 inhibitors, those with hyperdynamic personality, gastroesophageal reflux patients, and autonomic neuropathy patients. While taking this drug, side effects may include dry mouth, constipation, blurred vision, urinary retention, dry eyes, and more, with dry mouth and constipation being the most commonly reported. In severe cases, significant gastrointestinal adverse reactions may occur, and if symptoms are severe, immediate consultation with a physician is advised. This drug may cause drowsiness or blurred vision affecting driving or machinery operation, requiring caution. When taken with other anticholinergic drugs, effects or side effects may be amplified, therefore it is necessary to inform healthcare providers of any other medications being taken. Particularly, when combined with potent CYP3A4 inhibitors, the dosage should be limited, and patients with severe renal dysfunction or moderate liver dysfunction should avoid this combination. Safety during pregnancy has not been established and caution is necessary; during breastfeeding, it is advisable not to use this drug as it may be excreted in breast milk. Safety and efficacy in pediatric populations have not been established, therefore it should not be administered to children. In the case of overdose, appropriate treatment is required based on symptoms, and in severe cases, professional emergency care may be necessary. Prior to taking this drug, consult with a physician or pharmacist to ensure safe usage based on individual health status and history.

• Dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• fecal impaction
• colonic obstruction
• intestinal obstruction
• vascular-neurogenic edema
• nausea

This medication should be stored in a tightly closed container to protect it from air and moisture, and it is best stored at room temperature between 1°C and 30°C. Storing it this way helps maintain the drug's effectiveness for a longer period.

Appearance

Bright yellow round film-coated tablet

Package unit

100 tablets/PTP [10 tablets/PTP packaging x 10], 30 tablets/bottle, 100 tablets/bottle